T61589 |
C-Fms-IN-13
|
885704-58-5
|
98%
|
|
c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor (IC50= 17 nM). c-Fms-IN-13 is an anti-inflammatory agent.
|
T10648 |
C-Fms-IN-9
|
1628574-50-4
|
98%
|
|
c-Fms-IN-9 is a c-FMS inhibitor extracted from patent WO2014145023A1 (Example 7). It inhibits unphosphorylated c-FMS kinase (uFMS) and uKIT (IC50s: <0.01 μM and ...
|
T11734 |
K-80003
|
1292821-90-9
|
98%
|
|
K-80003 is a potent inhibitor of cancer cell growth and tRXRα-dependent Akt activation.
|
T1925 |
PLX647
|
873786-09-5
|
98%
|
|
PLX647 is a highly selective dual FMS/KIT kinase inhibitor (IC50: 28/16 nM).
|
T12505 |
PLX5622 hemifumarate
|
T12505
|
98%
|
|
PLX5622 hemifumarate is a highly selective brain penetrant and orally active CSF1R inhibitor with an IC 50 of 0.016 μM and Ki of 5.9 nM. PLX5622 hemifumarate all...
|
T10645 |
C-Fms-IN-6
|
1628574-81-1
|
98%
|
|
c-Fms-IN-6 is a potent inhibitor of c-FMS (IC50 ≤10 nM for unphosphorylated c-FMS) and also weakly inhibits unphosphorylated c-KIT and PDGFR (IC50: > 1 μM).
|
T10649 |
C-Fms-IN-3
|
885704-21-2
|
98%
|
|
c-Fms-IN-3 is a novel inhibitor of the c-FMS and can be used in studies about antirheumatic and anti-inflammatory diseases.
|
T2609 |
Masitinib
|
790299-79-5
|
98%
|
|
Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has ...
|
T10643 |
C-Fms-IN-1
|
885703-64-0
|
98%
|
|
c-Fms-IN-1 is an inhibitor of c-FMS kinase (IC50 = 0.8 nM).
|
T5586 |
CFMS Receptor Inhibitor II
|
959860-85-6
|
98%
|
|
cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor
|
T5172 |
AZ304
|
942507-42-8
|
98%
|
|
AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits BRAF (WT), BRAF (V600E), and wild type CRAF (IC50s: 79/38/68 nM).
|
T2624 |
OSI-930
|
728033-96-3
|
98%
|
|
OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel ...
|
T60087 |
CFMS Receptor Inhibitor IV
|
959626-45-0
|
98%
|
|
cFMS Receptor Inhibitor IV is an inhibitor of c-Fms tyrosine kinase.
|
TQ0015 |
PRN1371
|
1802929-43-6
|
98%
|
|
PRN1371 is a specific and potent FGFR1-4 and CSF1R inhibitor (IC50s: 0.6/1.3/4.1/19.3/8.1 nM for FGFR1/2/3/4 and CSF1R).
|
T13194 |
CSF1R-IN-2
|
2271119-26-5
|
98%
|
|
CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).
|
T2659 |
GW2580
|
870483-87-7
|
98%
|
|
GW2580 is a specific, oral-bioavailable CSF-1R inhibitor for c-FMS.
|
T3351 |
Onatasertib
|
1228013-30-6
|
98%
|
|
CC-223 is an orally available mTOR inhibitor with potential antitumor activity. CC-223 inhibits the activity of mTOR, which may result in the induction of tumor ...
|
T7100 |
PLX5622
|
1303420-67-8
|
98%
|
|
PLX-5622 is a highly selective brain penetrant and oral active CSF1R inhibitor.
|
T4376 |
Nampt-IN-1
|
1698878-14-6
|
98%
|
|
Nampt-IN-1 (LSN3154567) is a potent and selective NAMPT inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC50 of 3.1 nM.
|
T4315 |
Ki20227
|
623142-96-1
|
98%
|
|
Ki-20227 is a specific c-Fms tyrosine kinase(CSF1R) inhibitor (IC50: 2 nM). It also has certain inhibitory against VEGFR2(IC50: 12 nM) and c-Kit/PDGFRβ(IC50: 451...
|